Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noah Federman

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Advanced Functional Materials|April 2, 2026
Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry-Mediated Enrichment of Extracellular VesiclesYou-Ren Ji, Junseok Lee, Hyoyong Kim, et al.
Cancer Cell|May 16, 2018
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell CarcinomaMilica Momcilovic, Sean T Bailey, Jason T Lee, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The landscape of drug sensitivity and resistance in sarcomaAhmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Signal Transduction and Targeted Therapy|September 29, 2025
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistanceClaire M Storey, Mohamed Altai, Katharina Lückerath, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in OncologySmita Bhatia, Alberto S Pappo, Melissa Acquazzino, et al.
Nature Communications|July 2, 2025
Human cancer-targeted immunity via transgenic hematopoietic stem cell progenyTheodore S Nowicki, Nataly Naser Al Deen, Cole W Peters, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Advanced Functional Materials|April 2, 2026
Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry-Mediated Enrichment of Extracellular VesiclesYou-Ren Ji, Junseok Lee, Hyoyong Kim, et al.
Cancer Cell|May 16, 2018
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell CarcinomaMilica Momcilovic, Sean T Bailey, Jason T Lee, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The landscape of drug sensitivity and resistance in sarcomaAhmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Signal Transduction and Targeted Therapy|September 29, 2025
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistanceClaire M Storey, Mohamed Altai, Katharina Lückerath, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in OncologySmita Bhatia, Alberto S Pappo, Melissa Acquazzino, et al.
Nature Communications|July 2, 2025
Human cancer-targeted immunity via transgenic hematopoietic stem cell progenyTheodore S Nowicki, Nataly Naser Al Deen, Cole W Peters, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Pageof 12